The Atlantic

Readers Discuss Extreme Drug Prices—And What to Do About Them

“The public should receive a cut of any drug profits, just as any other investor might.”
Source: Bryan Woolston / Reuters

Big Pharma’s Go-To Defense of Soaring Drug Prices Doesn’t Add Up

Many pharmaceutical companies claim that exorbitant drug costs—some companies charge patients $100,000, $200,000, or even $500,000 a year—are necessary to fund expensive research projects that generate new drugs.

But “invoking high research costs to justify high drug prices,” Ezekiel J. Emanuel wrote last week, “is deceptive.” As even some pharmaceutical executives have acknowledged, he said, “there is no necessary link between a decline in drug prices and a decline in R&D.”


Too many people are focused on driving health costs down. It sounds intuitive, but it misses a bigger opportunity: making health costs most effective.

You’re reading a preview, subscribe to read more.

More from The Atlantic

The Atlantic8 min readAmerican Government
The Return of the John Birch Society
Michael Smart chuckled as he thought back to their banishment. Truthfully he couldn’t say for sure what the problem had been, why it was that in 2012, the John Birch Society—the far-right organization historically steeped in conspiracism and oppositi
The Atlantic17 min read
How America Became Addicted to Therapy
A few months ago, as I was absent-mindedly mending a pillow, I thought, I should quit therapy. Then I quickly suppressed the heresy. Among many people I know, therapy is like regular exercise or taking vitamin D: something a sensible person does rout
The Atlantic7 min readAmerican Government
The Americans Who Need Chaos
This is Work in Progress, a newsletter about work, technology, and how to solve some of America’s biggest problems. Sign up here. Several years ago, the political scientist Michael Bang Petersen, who is based in Denmark, wanted to understand why peop

Related Books & Audiobooks